References
- Vercellini P, Somigliana E, Daguati R, et al. Postoperative oral contraceptive exposure and risk of endometrioma recurrence. Am J Obstet Gynecol 2008;198:504.e1–5
- Jee BC, Lee JY, Suh CS, et al. Impact of GnRH agonist treatment on recurrence of ovarian endometriomas after conservative laparoscopic surgery. Fertil Steril 2009;91:40–50
- Sasagawa S, Shimizu Y, Kami H, et al. Dienogest is a selective progesterone receptor agonist in transactivation analysis with potent oral endometrial activity due to its efficient pharmacokinetic profile. Steroids 2008;73:222–31
- Harada T, Momoeda M, Taketani Y, et al. Dienogest is as effective as intranasal buserelin acetate for the relief of pain symptoms associated with endometriosis – a randomized, double-blind, multicenter, controlled trial. Fertil Steril 2008;91:675–81
- Strowitzki T, Marr J, Gerlinger C, et al. Dienogest is as effective as leuprolide acetate in treating the painful symptoms of endometriosis: a 24 week, randomized, multicentre, open-label trial. Hum Reprod 2010;25:633–41
- Momoeda M, Taketani Y. Randomized double-blind, multicenter, parallel-group dose-response study of dienogest in patients with endometriosis. Jpn Pharmacol Ther 2007;35:768–83 (in Japanese)
- Momoeda M, Harada T, Terakawa N, et al. Long-term use of dienogest for the treatment of endometriosis. J Obstet Gynaecol Res 2009;35:1069–76
- Petraglia F, Hornung D, Seitz C, et al. Reduced pelvic pain in women with endometoriosis: efficacy of long-term dienogest treatment. Arch Gynecol Obstet 2011;17:1941–7
- Kitawaki J, Kusuki I, Yamanaka K, Suganuma I. Maintenance therapy with dienogest following gonadotropin-releasing hormone agonist treatment for endometriosis-associated pelvic pain. Eur J Obstet Gynecol Repro Biol 2011;157:212–16
- Fu L, Osuga Y, Morimoto C, et al. Dienogest inhibits BrdU uptake with G0/G1 arrest in cultured endometriotic stromal cells. Fertil Steril 2008;89:1344–7
- Sasagawa S, Shimizu Y, Nagaoka T, et al. Dienogest, a selective progestin, reduces plasma estradiol level through induction of apoptosis of granulosa cells in the ovarian dominant follicle without follicle-stimulating hormone suppression in monkeys. J Endocrinol Invest 2008;31:636–41
- Moore C, Carol W, Graser T, et al. Influence of dienogest on ovulation in young fertile women. Clin Drug Invest 1999;18:271–8
- Yamanaka K, Xu B, Suganuma I, et al. Dienogest inhibits aromatase and cyclooxgenase-2 expression and prostaglandin E2 production in human endometriotic stromal cells in spheroid culture. Fertl Steril 2012;97:477–82
- Barbieri RL. Hormone treatment of endometriosis: the estrogen threshold hypothesis. Am J Obstet Gynecol 1992;166:645–6
- Barbieri RL. Endometriosis and the estrogen threshold theory relation to surgical and medical treatment. J Reprod Med 1998;43:287–92
- Köhler G, Faustmann TA, Gerlinger C, et al. A dose-ranging study to determine the efficacy and safety of 1, 2, and 4 mg of dienogest daily for endometriosis. Int J Gynecol Obstet 2010;108:21–5
- Irahara M, Harada T, Momoeda M, Tamaki Y. Hormonal and histological study on irregular genital bleeding in patients with endometriosis during treatment with dienogest, a novel progestational therapeutic agent. Reprod Med Biol 2007;6:223–8